James E. Muntz, M.D.

Education

Undergraduate Degree

Indiana University, Bloomington, Indiana

医学院

Baylor College of Medicine, Houston, Texas

Internship

St. Luke's Episcopal Program, Houston, Texas

居住

Baylor College of Medicine, Houston, Texas

联系信息

713.795.4847办公室
713.795.0774Fax

beplay苹果手机能用吗研究信息

双盲随机安慰剂对照研究确定迁移主义者的有效性和安全性（二羟胺甲酯鼻喷雾剂）2毫克，用于急性治疗急性偏头痛，在偏头痛家族中有或没有AURA。主席：罗伯特·里斯（Robert Rees），医学博士Muntz博士，调查员＃MU/TX-793-42。研究是临床试验研究＃793-42。协议DHE454。

The Effectiveness and Safety of Subcutaneous Enoxaparin compared to Intravenous Unfractionated Heparin for Patients Presenting with Unstable Angina or Non-Q Wave MI: An international double blind randomized parallel group, multi-center study (TIMI 11B). Protocol #RP54563-308. Regulatory #IND 31, 532. Sponsor: Rhone-Poulenc, Rorer Pharmaceuticals, Inc. Sub-Investigator.

A multicenter, randomized, parallel, assessor blind dose ranging study of subcutaneous SR90107A/ ORG31540 with a comparative control group of subcutaneous low molecular weight heparin in the prevention of deep vein thrombosis after elective total hip replacement. Principal Investigator, Houston, Texas, James E. Muntz, M.D.

对接受髋关节和膝关节手术的患者的血液管理分析（O.R.T.H.O.倡议）；JBJS中的Ortho Biotech，1/1999。

Organon Knee: A multicenter, multinational, randomized, double-blind, comparison of subcutaneous ORG31540/SR90107A, Study 095002, with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective major knee surgery or a revision. Principal Investigator, Houston, Texas, James E. Muntz, M.D.

A multicenter, multinational, randomized, double-blind, comparison of subcutaneous ORG31540/ SR90107A, Protocol N EFC2442, with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. Principal Investigator, Houston, Texas, James E. Muntz, M.D.

一项多中心，随机的双盲研究，比较了每天一次（O.D.）R90107A/ORG 31540的疗效和安全性，而每天两次（B.I.D）Enoxaparin在急性症状性深静脉血栓形成（DVT）方案的初始治疗中。协议编号EFC 2441。

A Randomized, Double–Blind, Comparative Study of H376/95 and Warfarin (Coumadin®) for the Prevention of Venous Thromboembolism following Total Knee Arthroplasty. Protocol No: 236.

A Phase II, Multicenter, Randomized, Open-Label Prospective Study to Evaluate Tinzaparin Versus Unfractionated Heparin In Subjects Who Are Receiving Long Term Warfarin and Require Parenteral Anticoagulation after the Discontinuation of Warfarin Therapy for an Invasive or Surgical Procedure.

A Phase II, Randomized, Double-Blind, Active Controlled (Enoxaparin), Parallel Group, Dose-Response Study of DPC 906 for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery.

A Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Two Dosing Regimens of Oral EMISPHERETM SNAC/Heparin with Subcutaneous Enoxaparin Sodium for the Prevention of Venous Thromboembolic Events Following Elective Total Hip Replacement Surgery.

一项双盲，随机，安慰剂对照研究，以评估单剂量，皮下（SC）darbepoetin alfa在接受术前自体捐赠（PAD）的受试者中的疗效和安全性，然后选择术前自体捐赠（PAD），然后选择全部髋关节矫正或双边膝关节替换手术。

A Multicenter, Randomized, Double-Blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolic Events in High Risk Patients Undergoing Abdominal Surgery. Sanofi-Synthelabo Protocol No: EFC3558.

A Randomized, Placebo-Controlled, Double-Blind, Pilot Study Comparing the Safety and Efficacy of the Use of Enoxaparin (Lovenox®) for Prophylaxis for the Prevention of Deep Vein Thrombosis after Arthroscopic Knee Surgery.

一项多中心，开放标签的，剂量反应（IA期）对ART-123（重组人类可溶性血栓统治）的研究，可通过皮下注射在预防术后静脉血栓形成的患者中，这是一项术后静脉血栓形成的患者。协议号A01-1329。

VanGogh DVT Trial – A multicenter international randomized open label, assessor blind non-inferiority study comparing the efficacy and safety of once weekly subcutaneous SAN and ORG 34006 with a combination of low molecular weight heparin and vitamin K antagonist in the treatment of acute symptomatic deep venous thrombosis.

VanGogh Pulmonary Embolism Trial – A multicenter international randomized open label, assessor blind non-inferiority study in the treatment of acute symptomatic pulmonary embolism.

国际多中心随机开放标签,double blind study comparing the efficacy and safety of once weekly subcutaneous SAN ORG with placebo in the long-term prevention of symptomatic venous thromboembolism in patients with symptomatic pulmonary embolism or deep venous thrombosis who completed 6 months of treatment with vitamin K antagonist or SAN ORG 34006.

导管指导的肌肉酶内血栓溶体和抗凝抗凝剂与抗凝治疗仅用于急性iLiofemoral静脉血栓形成：一项多中心国际随机试验。下肢深静脉血栓形成或抗凝溶血。首席研究员：医学博士Alan Lumsden。共同投资者：詹姆斯·E·曼兹（James E. Muntz），医学博士。

协议A5571010：2B期随机，多中心，剂量范围的研究，评估PD 0348292在预防静脉血栓栓塞事件（VTE）中的安全性和有效性，该受试者在接受选择性的单侧总膝盖替换中。

协议1160.24：重新动态。一项III期随机，平行组，双盲，主动对照研究，以研究两种不同剂量方案的功效和安全性（75mg第1天，然后是150mg第2天 - 完成和110mg Day 1与依诺氏蛋白30毫克相比，每天皮下持续12-15天的依克帕林（Enoxaparin）每天两次口服（胶囊）的dabigatran Etexilate（胶囊），预防初级选举总膝关节替代手术（重新杀入）的患者中预防静脉血栓栓塞。

Protocol ITI101724: A Fibrillation Rapid Trials. A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 372 mg and 500 mg) administered twice daily for 16 weeks, on top of aspirin (325 mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke.

协议CV185-010：2期随机，双盲（BMS-562247和Enoxaparin），主动对照（依诺肝素和华法蛋白），平行臂，剂量 - 反应研究，对XA抑制剂BMS-562247的剂量 - 反应研究选修全膝盖置换手术。

Publications

Publication Information

同行评审的文章

Muntz, JE, Perioperative Deep Venous Thrombosis and Pulmonary Embolism: Diagnosis, Management, and Treatment. National Association of Orthopedic Nurses (magazine): March/April 1997 supplement pages 25-29

Muntz, JE, Safe and Effective Use of Low Molecular Weight Heparin to Prevent Deep Venous Thrombosis in Orthopedic Patients.. Release date: November 1999.

Muntz, JE, Advances in the Prevention and Treatment of Thrombotic Complications in the Rehabilitation Patient, Wednesday November 10, 1999, Washington D.C.

Muntz, JE, : “Deep Vein Thrombosis and Pulmonary Embolism in the Perioperative Patient. American Journal of Managed Care: November 2000

Muntz, JE, Surgical Rounds; Risk Assessment Anticoagulation General Surgery Patient. Venous Thromboembolism – Bridging Therapy with Anticoagulation; pp. 9-11; October 2000.

Muntz, JE, Scientia Magazine; Guest Editor. Publication; Atherosclerosis and Thrombosis. February 2001.

McCuthen，J。；Muntz Je;路易斯·夸（Louis M. Kwong LM）；拉森先生；新疗法：骨科手术后的选择性凝血因子抑制静脉血栓栓塞疾病：突出显示新闻通讯，2001年3月预防的突破，2000年12月15日。

Muntz JE, Turpie AG, Ken Bauer K, Eriksson B, et al “The First Synthetic Factor Anti XA Inhibitor, Pentasaccharide (Arixtra) Compared with Low Molecular Weight Heparin to Prevent Venous Thromboembolism,” pages 119 and 120. Southern Orthopedic Association, Summer 2001, vol. 10, No. 2

Muntz，JE。优化静脉血栓栓塞预防的抗血栓疗法：《美国骨科杂志》，2002年4月补充，第1卷。xxxi，第4号

Kwong LM, Muntz JE: Thromboprophylaxis Dosing: The Relationship Between Timing of First Administration, Efficacy and Safety, Pages 16-20, The American Journal of Orthopedic Surgery, November 2002 Supplement, vol. XXXI, No. 11S

Muntz JE; Risks of Venous Thrombosis in Non-Large Joint Surgery. American Journal of Orthopedic Surgery February 2003, Vol 26 Number 2 Supplement pages 1-6.

Muntz JE; Orthopedic Pearls in Deep Vein Thrombosis: Questions Frequently Asked: Journal of Surgical Orthopedic Advances, Winter 2003, vol. 12, number 12, number 4, pages 225-227

肖恩·沙利文博士布鲁斯大卫dson, MD, Susan Khan, MD and James E. Muntz, MD, et al Cost Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism Using Patients Undergoing Major Orthopedic Surgery: Pharmacoeconomics 2003; 22 (9): 605-620

Muntz JE Major Bleeding Rates After Prophylaxis Against Venous Thromboembolism: Systemic Review Meta Analysis and Cost Implications: International Journal of Technology Assessment and Healthcare, 20:4 (2004), 405-414, copyright 2004, Cambridge University Press, printed in the USA

Muntz，JE，O’Conner PJ，Yin H，Vogenberg FR。与骨科患者的血栓预防相关的因素及其对预后的影响。骨科的Amer J。2007年4月3日，2007年（4），193-197。

Turpie AG，Bauer KA，Caprini JA，Comp PC，Gent M，Muntz JE；阿波罗调查人员。Fondaparinux与单独的间歇性气动压缩与间歇性压缩相结合，可预防腹部手术后的静脉血栓栓塞：一种随机的双盲比较。J血栓形成和止血2007年9月5日（9）1854-61。

James Muntz, M.D. Thromboprophylaxis in Orthopedic Surgery: How long Is Long Enough? The American Journal of Orthopedics. 2009 August, 32-35.

James E. Muntz, M.D., Franklin A. Michota, M.D. Prevention and Management of Venous Thromboembolism in the surgical patient: Options by surgery type and individual patient risk factors. The American Journal of Orthopedics. 2010 January, S11-20.

James E. Muntz，医学博士，富兰克林A. Michota，医学博士。手术患者中静脉血栓栓塞的预防和管理：手术类型和个体患者危险因素的选择，《美国外科杂志》，2010年11月，《补充》，第1卷。199，第1A号

James Muntz, M.D. Duration of DVT prophylaxis in the surgical patient and its relation to quality issues, The American Journal of Surgery, 2010

James Muntz, M.D. Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Total Hip Arthroplasty: The Promise of New Oral Anticoagulants, The Journal of Surgical Orthopedic Advances, Volume 20, Number 4, Winter 2011

Books and Chapters

Muntz，JE。骨科技术。19（4）：000-000，2004，Lippincott，Williams和Wilkins

Muntz，JE。骨科技术，2004年12月。骨科手术中静脉血栓栓塞的治疗

Muntz，JE。骨科技术，2004年12月，用于骨科手术中的预防性。